Application of Emerging Metabolomic Biomarkers in the Early Diagnosis of Vitiligo

DOI: https://doi.org/10.62517/jmhs.202505205

Author(s)

Wenli Ma, Ruhong Gao, Na Tang, Fengxia Lian*

Affiliation(s)

Ningxia Chinese medicine Research Center, Yinchuan, Ningxia, China *Corresponding Author

Abstract

Vitiligo, a common pigmentary skin disorder, necessitates early diagnosis for effective treatment and improved patient prognosis. This study explores the application value of emerging metabolomic biomarkers in the early diagnosis of vitiligo. Utilizing advanced techniques such as spatial metabolomics, we analyzed biological samples (e.g., serum, skin tissue) from vitiligo patients and healthy controls. Mass spectrometry imaging enabled the in-situ acquisition of extensive structural, quantitative, and spatial distribution data of endogenous metabolites, offering high specificity and throughput without complex labeling or sample pretreatment. Bioinformatics analysis of the data identified differential metabolites associated with the early onset of vitiligo, revealing their biological functions. Results indicated that certain emerging biomarkers, such as arginine, closely correlate with disease activity and severity in vitiligo patients, with significantly elevated serum arginine levels in progressive compared to stable patients. These emerging metabolites hold promise as reliable indicators for the early diagnosis of vitiligo, facilitating early detection and intervention, thereby enhancing clinical management.

Keywords

Vitiligo; Early Diagnosis; Emerging Metabolomic Biomarkers; Spatial Metabolomics; Arginine

References

[1] Yang X, Zhang X, Wang X, et al. Vitiligo: Epidemiology, comorbidities, quality of life and management in China[J]. Journal of the European Academy of Dermatology and Venereology, 2019, 33(10): 1937-1945. [2] Goh BK, Chong WS, Lee SH. Epidemiology of vitiligo in Singapore[J]. Journal of the American Academy of Dermatology, 2017, 76(2): 273-278. [3] Hann SK, Lee JH, Yoo KH. Diagnosis and differential diagnosis of vitiligo[J]. Clinical Dermatology, 2018, 36(4): 431-436. [4] Ding M, Zhen Z, Ju M, et al. Metabolomic profiling between vitiligo patients and healthy subjects in plateau exhibited significant differences with those in plain[J]. Clinical Immunology, 2023, 255: 109764. [5] Starcevic M, Marinkovic BA. Advances in genetics of vitiligo[J]. Pigment Cell & Melanoma Research, 2022, 35(1): 10-24. [6] Yan JQ. The expression of serum NES - 1 and IL - 25 in vitiligo patients and their correlation with disease staging[J]. Sichuan Journal of Physiological Sciences, 2023, 45(4): 701 - 703. [7] Zhang Y, Wang Y, Liu X, et al. Metabolomic study on the differences between qi - blood deficiency syndrome and liver - qi stagnation syndrome in vitiligo patients[J]. Chinese Journal of Integrative Medicine, 2021, 27(11): 869-875. [8] Harris JE, Grimes PE. Update on the pathogenesis of vitiligo[J]. Journal of the American Academy of Dermatology, 2019, 80(4): 1001-1013. [9] Jin Y, Han J, Yang X, et al. A genome - wide association study of vitiligo in the Chinese Han population[J]. Nature Genetics, 2017, 49(9): 1325-1330. [10] Lerner AB. The melanocyte and melanoma: Their relation to vitiligo[J]. Journal of Investigative Dermatology, 2018, 138(2): 289-296. [11] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation[J]. Science, 2016, 324(5930): 1029-1033.